Abstract 92P
Background
Bone metastases (BM) from colorectal cancer (CRC) are often accompanied by extraosseous metastases and have a dismal prognosis. The present study aims to find out the risk factors for BM in metastatic CRC (mCRC) and the prognostic factors for CRC patients with BM.
Methods
The study was based on a training cohort of 214 mCRC patients (of which 101 patients with BM) from our center, and a validation cohort of 511 mCRC patients from another institution (of which 173 patients with BM). The risk and prognostic nomogram for BM were identified using univariate and multivariate analyses. The goodness of fit, discrimination and calibration performance of the nomograms were assessed by R2, concordance statistics (C-statistics) and the calibration curve. The results were internally validated using bootstrap resampling in the training cohort and externally validated in the validation cohort.
Results
The novel BM risk nomogram comprised of seven variables (degree of tumor differentiation, N_stage, serum ALP, LDH, CEA, liver metastasis and lung metastasis). It showed good performance with an R2 of 0.447 and a C-statistics of 0.846 (95% CI, 0.793 to 0.898) in the training cohort, and an R2 of 0.325 and a C-statistics of 0.792 (95% CI, 0.750 to 0.834) in the validation cohort. The optimal cutoff value to identify individuals at low or high risk was 56% probability with the sensitivity of 71.3% and specificity of 89.4%. The prognostic nomogram included five factors (tumor differentiation, No. of extra-BM organs, No. of BM lesions, ALP and LDH) with an R2 of 0.284 and a C-statistics of 0.723 (95% CI, 0.657 to 0.789) in the training set. This nomogram was externally validated in the validation cohort with an R2 of 0.182 and a C-statistics of 0.682 (95% CI, 0.638 to 0.726).
Conclusions
The developed and validated risk nomogram and prognostic nomogram show good performance on predicting the occurrence of BM in mCRC and prognosis in CRC patients suffered from BM. The risk nomogram can be used as a cost-effective preliminary screening tool prior to bone scan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
260P - A phase I study of copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, in Chinese patients with relapsed indolent non-Hodgkin lymphoma (iNHL)
Presenter: Yuqin Song
Session: e-Poster Display Session
261P - Clinical outcomes of early-progressed follicular lymphoma in Korea: A multicenter, retrospective analysis
Presenter: Jun Ho Yi
Session: e-Poster Display Session
262P - Correlation between phosphorylated pI3K expression, phosphorylated AKT, and phosphorylated MTOR with serum dehydrogenase lactate level in non-Hodgkin lymphoma
Presenter: Hary Gustian
Session: e-Poster Display Session
263P - Good response to chemotherapy in primary CNS lymphoma may not translate into significant neurocognitive improvement in comatose patients
Presenter: Ryan Lim
Session: e-Poster Display Session
264P - Treatment outcome of primary testicular lymphoma patients treated in tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
271P - Cost-effectiveness of pembrolizumab as monotherapy or in combination with chemotherapy versus EXTREME regimen for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Taiwan
Presenter: Cheng Hsu Wang
Session: e-Poster Display Session
272P - Early metabolic changes in PET metrics over initial 8 weeks of treatment in patients with advanced head neck squamous cell carcinomas treated with chemotherapy
Presenter: Ashish Vaidya
Session: e-Poster Display Session
273P - Long term outcomes of locally advanced & borderline resectable esthesioneuroblastoma and sinonasal tumour with neuroendocrine differentiation treated with neoadjuvant chemotherapy
Presenter: Vikas Talreja
Session: e-Poster Display Session
274P - Comparing comorbidity indices in predicting 90-day mortality after radical radiotherapy for head and neck cancer
Presenter: Therese Tsui
Session: e-Poster Display Session
275P - Weekly paclitaxel, carboplatin and cetuximab (PCC) combination followed by nivolumab in platinum-sensitive recurrent and /or metastatic squamous cell carcinoma of head and neck: A double institution retrospective analysis from India
Presenter: Vivek Agarwala
Session: e-Poster Display Session